Literature DB >> 3943062

Chromosome changes in malignant mesothelioma.

Z Gibas, F P Li, K H Antman, S Bernal, R Stahel, A A Sandberg.   

Abstract

Cytogenetic study was made of mesothelioma cells from 14 patients. Metaphases were obtained from 12 tumors and revealed aneuploidy and clonal abnormalities in 9 specimens. In the two remaining cases, no metaphases were obtained. The cytogenetic abnormalities were complex, and up to 12 marker chromosomes were observed in the tumors. Rearrangements of chromosomes #1, #2, #3, #6, #9, #11, #17, and #22 were most frequently observed. Chromosome markers involved diverse bands, including several that are loci of oncogenes, fragile sites, and nonrandom rearrangements in other types of cancer. This study shows that the karyotypes of malignant mesothelioma can be analyzed by standard cytogenetic techniques. Additional studies of untreated mesothelioma may help to distinguish primary cytogenetic changes from effects of prior therapy in some of our patients.

Entities:  

Mesh:

Year:  1986        PMID: 3943062     DOI: 10.1016/0165-4608(86)90074-9

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  10 in total

1.  Syntenic relationships between genomic profiles of fiber-induced murine and human malignant mesothelioma.

Authors:  Didier Jean; Emilie Thomas; Elodie Manié; Annie Renier; Aurélien de Reynies; Céline Lecomte; Pascal Andujar; Jocelyne Fleury-Feith; Françoise Galateau-Sallé; Marco Giovannini; Jessica Zucman-Rossi; Marc-Henri Stern; Marie-Claude Jaurand
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

2.  Mechanisms of asbestos carcinogenesis and toxicity: the amphibole hypothesis revisited.

Authors:  B T Mossman
Journal:  Br J Ind Med       Date:  1993-08

3.  Integrated high-resolution array CGH and SKY analysis of homozygous deletions and other genomic alterations present in malignant mesothelioma cell lines.

Authors:  Geula Klorin; Ester Rozenblum; Oleg Glebov; Robert L Walker; Yoonsoo Park; Paul S Meltzer; Ilan R Kirsch; Frederic J Kaye; Anna V Roschke
Journal:  Cancer Genet       Date:  2013-07-05

4.  High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas.

Authors:  A B Bianchi; S I Mitsunaga; J Q Cheng; W M Klein; S C Jhanwar; B Seizinger; N Kley; A J Klein-Szanto; J R Testa
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

5.  Intraperitoneal cisplatin and etoposide in peritoneal mesothelioma: favorable outcome with a multimodality approach.

Authors:  C J Langer; N Rosenblum; M Hogan; S Nash; P Bagchi; F P LaCreta; R Catalano; R L Comis; P J O'Dwyer
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  Factors that impact susceptibility to fiber-induced health effects.

Authors:  Jennifer E Below; Nancy J Cox; Naomi K Fukagawa; Ari Hirvonen; Joseph R Testa
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2011       Impact factor: 6.393

7.  Chromosomal abnormalities and their correlations with asbestos exposure and survival in patients with mesothelioma.

Authors:  M Tiainen; L Tammilehto; J Rautonen; T Tuomi; K Mattson; S Knuutila
Journal:  Br J Cancer       Date:  1989-10       Impact factor: 7.640

Review 8.  Asbestos-induced lung disease.

Authors:  A R Brody
Journal:  Environ Health Perspect       Date:  1993-04       Impact factor: 9.031

Review 9.  Multiple mechanisms for the carcinogenic effects of asbestos and other mineral fibers.

Authors:  J C Barrett; P W Lamb; R W Wiseman
Journal:  Environ Health Perspect       Date:  1989-05       Impact factor: 9.031

Review 10.  Cellular and molecular mechanisms of asbestos carcinogenicity: implications for biopersistence.

Authors:  J C Barrett
Journal:  Environ Health Perspect       Date:  1994-10       Impact factor: 9.031

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.